Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Gerda B. Toth, Csanad G. Varallyay, Andrea Horvath, Mustafa R. Bashir, Peter L. Choyke, Heike E. Daldrup-Link, Edit Dosa, John Paul Finn, Seymur Gahramanov, Mukesh Harisinghani, Iain Macdougall, Alexander Neuwelt, Shreyas S. Vasanawala, Prakash Ambady, Ramon Barajas, Justin Cetas, Jeremy Ciporen, Thomas Deloughery, Nancy Doolittle, Rongwei (Rochelle) FuJohn Grinstead, Alexander Guimaraes, Bronwyn Hamilton, Xin Li, Heather L. McConnell, Leslie Muldoon, Gary Nesbit, Joao P. Netto, David Petterson, William Rooney, Daniel Schwartz, Laszlo Szidonya, Edward Neuwelt

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

Original languageEnglish (US)
Pages (from-to)47-66
Number of pages20
JournalKidney International
Volume92
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Ferrosoferric Oxide
Magnetic Resonance Imaging
Contrast Media
Central Nervous System
Atlases
Gadolinium
Cardiovascular System
Kidney
Safety
Pharmaceutical Preparations

Keywords

  • chronic kidney disease
  • magnetic resonance imaging
  • nephrotoxicity

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Toth, G. B., Varallyay, C. G., Horvath, A., Bashir, M. R., Choyke, P. L., Daldrup-Link, H. E., ... Neuwelt, E. (2017). Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney International, 92(1), 47-66. https://doi.org/10.1016/j.kint.2016.12.037

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. / Toth, Gerda B.; Varallyay, Csanad G.; Horvath, Andrea; Bashir, Mustafa R.; Choyke, Peter L.; Daldrup-Link, Heike E.; Dosa, Edit; Finn, John Paul; Gahramanov, Seymur; Harisinghani, Mukesh; Macdougall, Iain; Neuwelt, Alexander; Vasanawala, Shreyas S.; Ambady, Prakash; Barajas, Ramon; Cetas, Justin; Ciporen, Jeremy; Deloughery, Thomas; Doolittle, Nancy; Fu, Rongwei (Rochelle); Grinstead, John; Guimaraes, Alexander; Hamilton, Bronwyn; Li, Xin; McConnell, Heather L.; Muldoon, Leslie; Nesbit, Gary; Netto, Joao P.; Petterson, David; Rooney, William; Schwartz, Daniel; Szidonya, Laszlo; Neuwelt, Edward.

In: Kidney International, Vol. 92, No. 1, 01.07.2017, p. 47-66.

Research output: Contribution to journalReview article

Toth, GB, Varallyay, CG, Horvath, A, Bashir, MR, Choyke, PL, Daldrup-Link, HE, Dosa, E, Finn, JP, Gahramanov, S, Harisinghani, M, Macdougall, I, Neuwelt, A, Vasanawala, SS, Ambady, P, Barajas, R, Cetas, J, Ciporen, J, Deloughery, T, Doolittle, N, Fu, RR, Grinstead, J, Guimaraes, A, Hamilton, B, Li, X, McConnell, HL, Muldoon, L, Nesbit, G, Netto, JP, Petterson, D, Rooney, W, Schwartz, D, Szidonya, L & Neuwelt, E 2017, 'Current and potential imaging applications of ferumoxytol for magnetic resonance imaging', Kidney International, vol. 92, no. 1, pp. 47-66. https://doi.org/10.1016/j.kint.2016.12.037
Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney International. 2017 Jul 1;92(1):47-66. https://doi.org/10.1016/j.kint.2016.12.037
Toth, Gerda B. ; Varallyay, Csanad G. ; Horvath, Andrea ; Bashir, Mustafa R. ; Choyke, Peter L. ; Daldrup-Link, Heike E. ; Dosa, Edit ; Finn, John Paul ; Gahramanov, Seymur ; Harisinghani, Mukesh ; Macdougall, Iain ; Neuwelt, Alexander ; Vasanawala, Shreyas S. ; Ambady, Prakash ; Barajas, Ramon ; Cetas, Justin ; Ciporen, Jeremy ; Deloughery, Thomas ; Doolittle, Nancy ; Fu, Rongwei (Rochelle) ; Grinstead, John ; Guimaraes, Alexander ; Hamilton, Bronwyn ; Li, Xin ; McConnell, Heather L. ; Muldoon, Leslie ; Nesbit, Gary ; Netto, Joao P. ; Petterson, David ; Rooney, William ; Schwartz, Daniel ; Szidonya, Laszlo ; Neuwelt, Edward. / Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. In: Kidney International. 2017 ; Vol. 92, No. 1. pp. 47-66.
@article{aab0285aeaef4d2195ac485d7604520e,
title = "Current and potential imaging applications of ferumoxytol for magnetic resonance imaging",
abstract = "Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.",
keywords = "chronic kidney disease, magnetic resonance imaging, nephrotoxicity",
author = "Toth, {Gerda B.} and Varallyay, {Csanad G.} and Andrea Horvath and Bashir, {Mustafa R.} and Choyke, {Peter L.} and Daldrup-Link, {Heike E.} and Edit Dosa and Finn, {John Paul} and Seymur Gahramanov and Mukesh Harisinghani and Iain Macdougall and Alexander Neuwelt and Vasanawala, {Shreyas S.} and Prakash Ambady and Ramon Barajas and Justin Cetas and Jeremy Ciporen and Thomas Deloughery and Nancy Doolittle and Fu, {Rongwei (Rochelle)} and John Grinstead and Alexander Guimaraes and Bronwyn Hamilton and Xin Li and McConnell, {Heather L.} and Leslie Muldoon and Gary Nesbit and Netto, {Joao P.} and David Petterson and William Rooney and Daniel Schwartz and Laszlo Szidonya and Edward Neuwelt",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.kint.2016.12.037",
language = "English (US)",
volume = "92",
pages = "47--66",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

AU - Toth, Gerda B.

AU - Varallyay, Csanad G.

AU - Horvath, Andrea

AU - Bashir, Mustafa R.

AU - Choyke, Peter L.

AU - Daldrup-Link, Heike E.

AU - Dosa, Edit

AU - Finn, John Paul

AU - Gahramanov, Seymur

AU - Harisinghani, Mukesh

AU - Macdougall, Iain

AU - Neuwelt, Alexander

AU - Vasanawala, Shreyas S.

AU - Ambady, Prakash

AU - Barajas, Ramon

AU - Cetas, Justin

AU - Ciporen, Jeremy

AU - Deloughery, Thomas

AU - Doolittle, Nancy

AU - Fu, Rongwei (Rochelle)

AU - Grinstead, John

AU - Guimaraes, Alexander

AU - Hamilton, Bronwyn

AU - Li, Xin

AU - McConnell, Heather L.

AU - Muldoon, Leslie

AU - Nesbit, Gary

AU - Netto, Joao P.

AU - Petterson, David

AU - Rooney, William

AU - Schwartz, Daniel

AU - Szidonya, Laszlo

AU - Neuwelt, Edward

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

AB - Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

KW - chronic kidney disease

KW - magnetic resonance imaging

KW - nephrotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85018617541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018617541&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.12.037

DO - 10.1016/j.kint.2016.12.037

M3 - Review article

C2 - 28434822

AN - SCOPUS:85018617541

VL - 92

SP - 47

EP - 66

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -